Vitamin B supplementation, homocysteine levels, and the risk of cerebrovascular disease: A meta-analysis

Neurology

Volumn 81, Issue 15, 2013, Pages 1298-1307

  Ji, Yan ^a   Tan, Song ^a   Xu, Yuming ^a   Chandra, Avinash ^b   Shi, Changhe ^a   Song, Bo ^a   Qin, Jie ^a   Gao, Yuan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BRAIN HEMORRHAGE; CEREAL; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; DISEASE ASSOCIATION; EMBASE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; MEDLINE; META ANALYSIS; NEOPLASM; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; VITAMIN BLOOD LEVEL; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION;

CEREBROVASCULAR DISORDERS; DIETARY SUPPLEMENTS; FOLLOW-UP STUDIES; HOMOCYSTEINE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN B COMPLEX;

EID: 84888243249     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182a823cc     Document Type: Article

References (40)

1. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-1057.
2. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 2005;365:224-232.
3. Martí-Carvajal AJ, Solà I, Lathyris D, Karakitsiou DE, Simancas-Racines D. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev 2013;1:CD006612.
4. Holmes MV, Newcombe P, Hubacek JA, et al. Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomized trials. Lancet 2011;378:584-594.
5. Yang Q, Botto LD, Erickson JD, Berry RJ, Sambell C, Johansen H. Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 2006;113:1335-1343.
6. Spence DL, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 2005;36:2404-2409.
7. Heinz J, Kropf S, Domröse U, et al. B vitamins and the risk of total mortality and cardiovascular disease in endstage renal disease: results of a randomized controlled trial. Circulation 2010;121:1432-1438.
8. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; HOPE2 Investigators. Homocysteine-lowering therapy and stroke risk, severity and disability: additional findings from the HOPE2 Trial. Stroke 2009;40:1365-1372.
9. House AA, Eliasziw M, Cattran DC, et al. Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA 2010;303:1603-1609.
10. Bostom AG, Carpenter MA, Kusek JW, et al. Homocysteinelowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial. Circulation 2011;123:1763-1770.
11. Mason JB, Dickstein A, Jacques PF, et al. A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: a hypothesis. Cancer Epidemiol Biomarkers Prev 2007;16:1325-1329.
12. Hankey GJ, Eikelboom JW, Yi Q, et al. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischaemic attack: a post-hoc subanalysis of VITATOPS, a randomised, placebo-controlled trial. Lancet Neurol 2012;11:512-520.
13. Spence JD. Nutrition and stroke prevention. Stroke 2006;37:2430-2435.
14. Galan P, Kesse-Guyot E, Czernichow S, et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010;341:c6273.
15. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999;354:1896-1900.
16. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
17. The VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the vitamins to prevent stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 2010;9:855-865.
18. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-1588.
19. Study of the Effectiveness of additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group; Armitage JM, Bowman L, et al. Effects of homocysteinelowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA 2010;303:2486-2494.
20. Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteinelowering B vitamins after coronary angiography a randomized controlled trial. JAMA 2008;300:795-804.
21. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298:1163-1171.
22. Albert CM, Cook NR, Gaziano M, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008;299:2027-2036.
23. Mark SD, Wang W, Fraumeni JF, et al. Lowered risks of hypertension and cerebrovascular disease after vitamin/mineral supplementation: the Linxian Nutrition Intervention Trial. Am J Epidemiol 1996;143:658-664.
24. Zoungas S, McGrath BP, Branley P, et al. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial. J Am Coll Cardiol 2006;47:1108-1116.
25. Mann JF, Sheridan P, McQueen MJ, et al. Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease: results of the renal Hope-2 study. Nephrol Dial Transplant 2008;23:645-653.
26. Lee M, Hong KS, Chang SC, Saver JL. Efficacy of homocysteine-lowering therapy with folic acid in stroke prevention: a meta-analysis. Stroke 2010;41:1205-1212.
27. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004;15:420-426.
28. Liem AH, van Boven AJ, Veeger NJ, et al. Efficacy of folic acid when added to statin therapy in patients with hypercholesterolemia following acute myocardial infarction: a randomized pilot trial. Int J Cardiol 2004;93:175-179.
29. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, van Veldhuisen DJ. Secondary prevention with folic acid: results of the GOES extension study. Heart 2005;91:1213-1214.
30. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteinelowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif 2006;24:379-386.
31. Brattstrom L. Vitamins as homocysteine-lowering agents. J Nutr 1996;126(suppl 4):1276S-1280S.
32. Rajan S, Wallace JI, Brodkin KI, Beresford SA, Allen RH, Stabler SP. Response of elevated methylmalonic acid to three dose levels of oral cobalamin in older adults. J Am Geriatr Soc 2002;50:1789-1795.
33. Tighe P, Ward M, McNulty H, et al. A dose-finding trial of the effect of long-term folic acid intervention: implications for food fortification policy. Am J Clin Nutr 2011;93:11-18.
34. Spence JD, Cordy P, Kortas C, Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst (e) ine in hemodialysis patients: no difference between 1 and 5 mg daily. Am J Nephrol 1999;19:405-410.
35. Menon V, Sarnak MJ, Greene T, et al. Relationship between homocysteine and mortality in chronic kidney disease. Circulation 2006;113:1572-1577.
36. Tayama J, Munakata M, Yoshinaga K, Toyota T. Higher plasma homocysteine concentration is associated with more advanced systemic arterial stiffness and greater blood pressure response to stress in hypertensive patients. Hypertens Res 2006;29:403-409.
37. Dayi H, Xip X. Management of H-type hypertension: a new idea of stroke prevention. Chin J Intern Med 2008;47:976-978.
38. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007;6:830-838.
39. Ebbing M, Bønaa KH, Nygård O, et al. Cancer incidence and mortality after treatment with folic acid and vitamin B12. JAMA 2009;302:2119-2126.
40. Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: metaanalyses of data on 50, 000 individuals. Lancet 2013;381:1029-1036.